←
Declan Murphy7,361 posts
Declan Murphy avatar✓

Declan Murphy ✓

@declangmurphy

Urologist & Director of GU Oncology, Peter MacCallum Cancer Centre | Professor, University of Melbourne | Podcasting at GU Cast. Views my own. RT = endorsement

◷ Joined March 2011▧ 1,319 Photos and videos
Gil Morgan, MD avatar
⟳ Declan Murphy retweeted
Gil Morgan, MD@weoncologists·Nov 2

Fewer patients needing radiotherapy after surgery (salvage RT 15.7% vs 27.8%) really matters to patients and their quality of life. Great to see perioperative apalutamide adding to the options we can offer. Congratulations to all the authors and thanks to all the patients and teams who made this trial possible !

Arun Azad avatar
⟳ Declan Murphy retweeted
Arun Azad@AzadOncology·Oct 31

Out now in @TheLancetOncol: biomarker data from TALAPRO-2 (Enza+/Tala) in mCR #ProstateCancer Key data: 1. 81% concordance b/w ctDNA & tissue 2. Baseline ctDNA- & CTC0 strongly prognostic 3. Conversion of ctDNA & CTC at wk 9 strongly prognostic. Link 👉 rb.gy/347dc4

Post attachmentPost attachmentPost attachmentPost attachment
Ashish M. Kamat, MD, MBBS avatar
⟳ Declan Murphy retweeted
Ashish M. Kamat, MD, MBBS@UroDocAsh·Oct 28

We need thoughtful, forward-thinking surgeons like @wandering_gu at the ASCO leadership table, bringing the surgical perspective to how we advance multidisciplinary cancer care. Todd Morgan is an exceptional surgeon and researcher, and someone I have tremendous respect for. Voting is now open asco.org/about-asco/asco-ove…

Post attachment
OncoAlert avatar
⟳ Declan Murphy retweeted
OncoAlert@OncoAlert·Oct 26

Dear GU colleagues at #ESMO26! Dr Silke Gillessen & Dr. Aurelius Omlin🇨🇭 invite you to the inaugural LPCCC – Localised Prostate Cancer Consensus Conference! 🔬 CALL FOR ABSTRACTS NOW OPEN! 👉 Submit your abstract: apccc.org/call-for-abstracts 📅 LPCCC 2027 | 29 April – 1 May 2027 We invite colleagues in #ProstateCancer to submit their abstracts and contribute to shaping the discussion on the diagnosis and clinical management of men with localised prostate cancer. LPCCC marks an exciting new chapter for the APCCC family, extending the consensus-conference concept to localised disease, with a particular focus on areas where evidence, guidelines and clinical practice leave important questions unanswered. Two days of high-level presentations, expert discussion and debate will bring together the latest evidence and perspectives to address the questions that matter most in everyday clinical practice. We look forward to your contributions! #LPCCC27 #ProstateCancer #ESMO26 @APCCC_Lugano @BertrandTOMBAL @ChrisSweens1 @jmmrad @drjefstathiou @CaPsurvivorship @LoebStacy @charlesryanmd @AarmstrongDuke @Ecastromarcos @LVM_Walz @piet_ost @Nicola_Fossati @AnthonyMJoshua @Prof_Nick_James @VedangMurthy @AttardLab @Silke_Gillessen @AOmlin @ProfKHerrmann 📣 Also tagging: @AmandaNizamMD @scocmem @nataliagandur @gu_onc @tompowles1 @brian_rini @declangmurphy @cdanicas @neerajaiims

1:59
Himanshu Nagar avatar
⟳ Declan Murphy retweeted
Himanshu Nagar@HimanshuNagarMD·Oct 24

Putting STAMPEDE, ENZARAD, PROTEUS & DASL into context with the latest #ESMO26 updates: STAMPEDE: Abiraterone-based intensification improved MFS AND OS, predominantly with RT. New #ESMO26 Decipher data suggests differential abi benefit in cN0 disease (interaction P=.01); using this to omit treatment still requires validation. ENZARAD: At 8 years, MFS was 74% vs 72% (HR 0.88; P=.34). No significant overall MFS benefit from enza + ADT/RT. The cN1/planned pelvic RT subgroup signals remain hypothesis-generating. DASL: new at #ESMO26: 1,106 patients; 96 weeks of daro v. placebo + ADT + prostate/bed AND pelvic RT. Four-year conventional-imaging MFS: 95% vs 88% (HR 0.42). Very-high-risk population, including selected postoperative patients. Interim analysis; OS immature. PROTEUS main trial: Perioperative apa + ADT improved 5-year PSMA-inclusive MFS versus ADT alone: 78.2% vs 73.5% (HR 0.80). Conventional-imaging MFS was not statistically significant. #ESMO26 post hoc PSA-response analysis adds prognostic information. PROTEUS randomized substudy: new at #ESMO26: Perioperative apa/ADT + RP/PLND (n=102) v. immediate RP/PLND (n=306). At 37.8 months’ follow-up: • 3-year EFS: 63.0% vs 41.4%; HR 0.38. • Secondary PSMA-inclusive MFS: HR 0.49; nominal P=.0193. • Subsequent postoperative RT: 20% vs 43%. The substudy strengthens a "perioperative strategy". But conventional-imaging entry followed by PSMA-inclusive endpoints matters. PSA-based EFS, conventional MFS and PSMA-inclusive MFS are different endpoints. These trials support specific intensification strategies; they cannot rank the drugs or establish RP-versus-RT superiority. The decision remains who benefits enough to justify the ENTIRE treatment burden.

Michael Hofman avatar
⟳ Declan Murphy retweeted
Michael Hofman@DrMHofman·Oct 24

LuCAB at #ESMO26 - Combination Lu-177 PSMA-617 + cabazitaxel in mCRPC, accepted in @TheLancetOncol Adding taxane chemotherapy to LuPSMA may overcome heterogeneous PSMA expression and act as a radiosensitiser. 35 pts, post-docetaxel + ARPI: 🧪 No DLTs: cabazitaxel 20 mg/m2 + 7.4 GBq LuPSMA ⚠️ G3 TRAEs 24%, no G4/5 📈 RP2D (n=26): PSA50 73%, rPFS 10.9 mo, OS 16.5 mo Impressive outcomes in an unfavourable cohort (29% M1c). Randomised trials needed: chemo + LuPSMA together or in sequence? 🙏 Led by @LouiseKostos & @AzadOncology with @ButeauJames , Grace Kong, @pj_physics, @DrBenTran, @MHaskali, @declangmurphy @PeterMacCC and @drlouiseemmett @StVincentsSyd Above all, thank you to the patients and families who took part. Funded by @PCFnews through @pros_tic , with PSMA-617 supplied by @Novartis plus additional support. @myESMO

Deborah Mukherji avatar
⟳ Declan Murphy retweeted
Deborah Mukherji@dmukherji·Oct 24

PROTEUS substudy results at #ESMO26 Perioperative apalutamide + ADT vs surgery alone in high-risk localized #ProstateCancer EFS HR 0.38 MFS HR 0.49 Subsequent treatment at 3 years: 35% vs 68% Compelling evidence for perioperative intensification @OncoAlert

Post attachment
Michael Hofman avatar
⟳ Declan Murphy retweeted
Michael Hofman@DrMHofman·Oct 19

Pushing Terbium-161 PSMA Theranostics to 9.5 GBq - VIOLET Clinical Trial results at the #EANM26 @EANM_NucMed Terbium-161 emits beta radiation like lutetium-177, plus ultra-short range Auger and conversion electrons that may better target micrometastases. Our first-in-human VIOLET trial established safety up to 7.4 GBq (Lancet Oncology 2025). So we asked: can we go higher? 12 men with mCRPC, 9.5 GBq, up to 6 cycles: - Remarkably well tolerated: just 1 grade 3 toxicity (anaemia) - PSA50 response 75%, PSA90 response 33% - Median PSA-PFS and rPFS not reached The answer is yes - and we’re not stopping ... Cohort C, a dose-dense cohort with shorter intervals between early cycles, is now underway. Huge thanks to @PCF_Science Young Investigators @ButeauJames , @LouiseKostos and @AzadOncology , and to the whole @PeterMacCC @pros_tic team who made this investigator-initiated trial possible. Grateful to @Isotopia_Global and the for their support #TOP (Top Rated Oral Presentation)

Andrea Necchi, MD, FASCO avatar
⟳ Declan Murphy retweeted
Andrea Necchi, MD, FASCO@AndreaNecchi·Oct 23

This further #ESMO26 @ESMO_Open simultaneous publication is very important for me. @SanRaffaeleMI @MyUniSR Outcomes of pts with MIBC who decline RC in perioperative setting: Take-home message: 1. cCR (Milan criteria) is a reliable biomarker and indicator of outcomes with Systemic Rx and reTURBT 2. Pts who do not get cCR could have a very poor prognosis under bladder-saving approaches > intensification with RC/chemoRT is very much needed Looking forward to ongoing trials (eg EV209, EV309). Congrats to the entire team, also getting Best Poster! @OncoAlert @myESMO @CMercinelli @Anto_cigliola @BrigidaMaiorano @urotoday Piacentini Nasso Serafin et al. Outcomes of patients with muscle-invasive bladder cancer who declined radical cystectomy in perioperative therapy trials conducted at San Raffaele Comprehensive Cancer Center - ESMO Open esmoopen.com/article/S2059-7…

Post attachment
Firas Abdollah avatar
⟳ Declan Murphy retweeted
Firas Abdollah@DrFAbdollah·Sep 5

In a 10-yr follow-up of a randomized trial, Retzius-sparing RARP (better early continence) showed worse long-term cancer control than the anterior approach — 2.64x higher progression risk after adjustment. Post-hoc, hypothesis-generating. free link:authors.elsevier.com/a/1njm6…

Post attachment